Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women

Yoon Sok Chung, Sungkil Lim, Ho Yeon Chung, In Kyu Lee, Il Hyung Park, Ghi Su Kim, Yong Ki Min, Moo Il Kang, Dong Jin Chung, Yong Ki Kim, Woong Hwan Choi, Min Ho Shong, Ji Hyun Park, Dong Won Byun, Hyun Koo Yoon, Chan Soo Shin, Yil Seob Lee, Nam Hee Kwon

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Patient preferences, convenience, and bone turnover markers were evaluated for the monthly ibandronate over the weekly risedronate regimen in Korean postmenopausal osteoporotic women. This was a 6-month, prospective, randomized, open-label, multicenter study with a two-period and two-sequence crossover treatment design. After a 30-day screening period, eligible participants with postmenopausal osteoporosis were randomized to receive either monthly oral ibandronate 150 mg for 3 months followed by weekly oral risedronate 35 mg for 12 weeks (sequence A) or the same regimen in reverse order (sequence B). Patient preference and convenience were evaluated by questionnaire. The changes in serum C-telopeptide after 3 months of treatment were analyzed. A total of 365 patients were enrolled in this study (sequence A 182, sequence B 183). Of patients expressing a preference (83.4%), 74.8% preferred the monthly ibandronate regimen over the weekly regimen (25.2%). More women stated that the monthly ibandronate regimen was more convenient (84.2%) than the weekly regimen (15.8%). There was no significant difference in the change in bone turnover marker between the two treatments. The two regimens were similarly tolerable. There were fewer adverse events in the monthly ibandronate group compared to the weekly risedronate group in terms of gastrointestinal side effects (nausea and abdominal distension). This study revealed a strong preference and convenience for monthly ibandronate over weekly risedronate in Korean postmenopausal osteoporotic women. There was no significant difference in change of bone turnover marker and safety profile between the two regimens.

Original languageEnglish
Pages (from-to)389-397
Number of pages9
JournalCalcified Tissue International
Volume85
Issue number5
DOIs
Publication statusPublished - 2009 Nov 1

Fingerprint

Bone Remodeling
Patient Preference
Postmenopausal Osteoporosis
Cross-Over Studies
Nausea
Multicenter Studies
Risedronate Sodium
ibandronic acid
Therapeutics
Safety
Serum

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

Cite this

Chung, Yoon Sok ; Lim, Sungkil ; Chung, Ho Yeon ; Lee, In Kyu ; Park, Il Hyung ; Kim, Ghi Su ; Min, Yong Ki ; Kang, Moo Il ; Chung, Dong Jin ; Kim, Yong Ki ; Choi, Woong Hwan ; Shong, Min Ho ; Park, Ji Hyun ; Byun, Dong Won ; Yoon, Hyun Koo ; Shin, Chan Soo ; Lee, Yil Seob ; Kwon, Nam Hee. / Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women. In: Calcified Tissue International. 2009 ; Vol. 85, No. 5. pp. 389-397.
@article{117f47463a1a4f808846b6085cd394bc,
title = "Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women",
abstract = "Patient preferences, convenience, and bone turnover markers were evaluated for the monthly ibandronate over the weekly risedronate regimen in Korean postmenopausal osteoporotic women. This was a 6-month, prospective, randomized, open-label, multicenter study with a two-period and two-sequence crossover treatment design. After a 30-day screening period, eligible participants with postmenopausal osteoporosis were randomized to receive either monthly oral ibandronate 150 mg for 3 months followed by weekly oral risedronate 35 mg for 12 weeks (sequence A) or the same regimen in reverse order (sequence B). Patient preference and convenience were evaluated by questionnaire. The changes in serum C-telopeptide after 3 months of treatment were analyzed. A total of 365 patients were enrolled in this study (sequence A 182, sequence B 183). Of patients expressing a preference (83.4{\%}), 74.8{\%} preferred the monthly ibandronate regimen over the weekly regimen (25.2{\%}). More women stated that the monthly ibandronate regimen was more convenient (84.2{\%}) than the weekly regimen (15.8{\%}). There was no significant difference in the change in bone turnover marker between the two treatments. The two regimens were similarly tolerable. There were fewer adverse events in the monthly ibandronate group compared to the weekly risedronate group in terms of gastrointestinal side effects (nausea and abdominal distension). This study revealed a strong preference and convenience for monthly ibandronate over weekly risedronate in Korean postmenopausal osteoporotic women. There was no significant difference in change of bone turnover marker and safety profile between the two regimens.",
author = "Chung, {Yoon Sok} and Sungkil Lim and Chung, {Ho Yeon} and Lee, {In Kyu} and Park, {Il Hyung} and Kim, {Ghi Su} and Min, {Yong Ki} and Kang, {Moo Il} and Chung, {Dong Jin} and Kim, {Yong Ki} and Choi, {Woong Hwan} and Shong, {Min Ho} and Park, {Ji Hyun} and Byun, {Dong Won} and Yoon, {Hyun Koo} and Shin, {Chan Soo} and Lee, {Yil Seob} and Kwon, {Nam Hee}",
year = "2009",
month = "11",
day = "1",
doi = "10.1007/s00223-009-9294-y",
language = "English",
volume = "85",
pages = "389--397",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "5",

}

Chung, YS, Lim, S, Chung, HY, Lee, IK, Park, IH, Kim, GS, Min, YK, Kang, MI, Chung, DJ, Kim, YK, Choi, WH, Shong, MH, Park, JH, Byun, DW, Yoon, HK, Shin, CS, Lee, YS & Kwon, NH 2009, 'Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women', Calcified Tissue International, vol. 85, no. 5, pp. 389-397. https://doi.org/10.1007/s00223-009-9294-y

Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women. / Chung, Yoon Sok; Lim, Sungkil; Chung, Ho Yeon; Lee, In Kyu; Park, Il Hyung; Kim, Ghi Su; Min, Yong Ki; Kang, Moo Il; Chung, Dong Jin; Kim, Yong Ki; Choi, Woong Hwan; Shong, Min Ho; Park, Ji Hyun; Byun, Dong Won; Yoon, Hyun Koo; Shin, Chan Soo; Lee, Yil Seob; Kwon, Nam Hee.

In: Calcified Tissue International, Vol. 85, No. 5, 01.11.2009, p. 389-397.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women

AU - Chung, Yoon Sok

AU - Lim, Sungkil

AU - Chung, Ho Yeon

AU - Lee, In Kyu

AU - Park, Il Hyung

AU - Kim, Ghi Su

AU - Min, Yong Ki

AU - Kang, Moo Il

AU - Chung, Dong Jin

AU - Kim, Yong Ki

AU - Choi, Woong Hwan

AU - Shong, Min Ho

AU - Park, Ji Hyun

AU - Byun, Dong Won

AU - Yoon, Hyun Koo

AU - Shin, Chan Soo

AU - Lee, Yil Seob

AU - Kwon, Nam Hee

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Patient preferences, convenience, and bone turnover markers were evaluated for the monthly ibandronate over the weekly risedronate regimen in Korean postmenopausal osteoporotic women. This was a 6-month, prospective, randomized, open-label, multicenter study with a two-period and two-sequence crossover treatment design. After a 30-day screening period, eligible participants with postmenopausal osteoporosis were randomized to receive either monthly oral ibandronate 150 mg for 3 months followed by weekly oral risedronate 35 mg for 12 weeks (sequence A) or the same regimen in reverse order (sequence B). Patient preference and convenience were evaluated by questionnaire. The changes in serum C-telopeptide after 3 months of treatment were analyzed. A total of 365 patients were enrolled in this study (sequence A 182, sequence B 183). Of patients expressing a preference (83.4%), 74.8% preferred the monthly ibandronate regimen over the weekly regimen (25.2%). More women stated that the monthly ibandronate regimen was more convenient (84.2%) than the weekly regimen (15.8%). There was no significant difference in the change in bone turnover marker between the two treatments. The two regimens were similarly tolerable. There were fewer adverse events in the monthly ibandronate group compared to the weekly risedronate group in terms of gastrointestinal side effects (nausea and abdominal distension). This study revealed a strong preference and convenience for monthly ibandronate over weekly risedronate in Korean postmenopausal osteoporotic women. There was no significant difference in change of bone turnover marker and safety profile between the two regimens.

AB - Patient preferences, convenience, and bone turnover markers were evaluated for the monthly ibandronate over the weekly risedronate regimen in Korean postmenopausal osteoporotic women. This was a 6-month, prospective, randomized, open-label, multicenter study with a two-period and two-sequence crossover treatment design. After a 30-day screening period, eligible participants with postmenopausal osteoporosis were randomized to receive either monthly oral ibandronate 150 mg for 3 months followed by weekly oral risedronate 35 mg for 12 weeks (sequence A) or the same regimen in reverse order (sequence B). Patient preference and convenience were evaluated by questionnaire. The changes in serum C-telopeptide after 3 months of treatment were analyzed. A total of 365 patients were enrolled in this study (sequence A 182, sequence B 183). Of patients expressing a preference (83.4%), 74.8% preferred the monthly ibandronate regimen over the weekly regimen (25.2%). More women stated that the monthly ibandronate regimen was more convenient (84.2%) than the weekly regimen (15.8%). There was no significant difference in the change in bone turnover marker between the two treatments. The two regimens were similarly tolerable. There were fewer adverse events in the monthly ibandronate group compared to the weekly risedronate group in terms of gastrointestinal side effects (nausea and abdominal distension). This study revealed a strong preference and convenience for monthly ibandronate over weekly risedronate in Korean postmenopausal osteoporotic women. There was no significant difference in change of bone turnover marker and safety profile between the two regimens.

UR - http://www.scopus.com/inward/record.url?scp=70449535526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449535526&partnerID=8YFLogxK

U2 - 10.1007/s00223-009-9294-y

DO - 10.1007/s00223-009-9294-y

M3 - Article

VL - 85

SP - 389

EP - 397

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 5

ER -